Barclays PLC Purchases 10,803 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Barclays PLC grew its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 20.1% in the third quarter, HoldingsChannel.com reports. The firm owned 64,423 shares of the medical equipment provider’s stock after acquiring an additional 10,803 shares during the period. Barclays PLC’s holdings in BioLife Solutions were worth $1,613,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Fred Alger Management LLC raised its holdings in BioLife Solutions by 6.0% during the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after acquiring an additional 88,840 shares during the period. State Street Corp grew its position in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in BioLife Solutions by 9.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after purchasing an additional 66,422 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in shares of BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after buying an additional 262,504 shares in the last quarter. Finally, Curi RMB Capital LLC boosted its holdings in shares of BioLife Solutions by 0.5% during the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after purchasing an additional 2,283 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. KeyCorp increased their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Craig Hallum lifted their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Benchmark reissued a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, HC Wainwright cut their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

BioLife Solutions Trading Down 1.6 %

BLFS stock opened at $26.59 on Friday. BioLife Solutions, Inc. has a 12 month low of $14.50 and a 12 month high of $28.88. The firm’s 50-day moving average is $25.22 and its 200 day moving average is $23.88. The company has a market capitalization of $1.23 billion, a PE ratio of -25.08 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

Insiders Place Their Bets

In other BioLife Solutions news, EVP Aby J. Mathew sold 17,604 shares of BioLife Solutions stock in a transaction on Monday, November 18th. The stock was sold at an average price of $20.05, for a total transaction of $352,960.20. Following the completion of the sale, the executive vice president now directly owns 284,442 shares of the company’s stock, valued at $5,703,062.10. The trade was a 5.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 64,259 shares of company stock worth $1,424,708 in the last three months. Corporate insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.